Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cryolife (CRY)

Cryolife (CRY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,018,234
  • Shares Outstanding, K 37,504
  • Annual Sales, $ 276,220 K
  • Annual Income, $ 1,720 K
  • 60-Month Beta 0.67
  • Price/Sales 3.74
  • Price/Cash Flow 36.69
  • Price/Book 3.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 0.02
  • Number of Estimates 1
  • High Estimate 0.02
  • Low Estimate 0.02
  • Prior Year 0.04
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.22 +0.08%
on 02/19/20
31.77 -17.41%
on 01/29/20
-3.75 (-12.50%)
since 01/17/20
3-Month
23.88 +9.90%
on 11/22/19
31.77 -17.41%
on 01/29/20
+1.64 (+6.67%)
since 11/19/19
52-Week
20.76 +26.40%
on 10/31/19
33.00 -20.48%
on 07/31/19
-2.60 (-9.02%)
since 02/19/19

Most Recent Stories

More News
Noteworthy Tuesday Option Activity: CRY, IIPR, ZS

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in CryoLife, Inc. , where a total volume of 1,525 contracts has been traded thus far today,...

CRY : 26.24 (-3.35%)
After Yesterday's Decline of 7.39%, Cryolife Inc Offers Investors Better Value

Cryolife Inc (NYSE:CRY) traded in a range yesterday that spanned from a low of $27.47 to a high of $29.03. Yesterday, the shares fell 7.4%, which took the trading range below the 3-day low of $29.92...

CRY : 26.24 (-3.35%)
CryoLife Reports Fourth Quarter and Full Year 2019 Financial Results

https://mma.prnewswire.com/media/324116/cryolife__inc__logo.jpg

CRY : 26.24 (-3.35%)
CryoLife (CRY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

CryoLife (CRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CRY : 26.24 (-3.35%)
Valvular Heart Disease Treatment Market 2020 Global Industry Trends, Statistics, Competition Strategies, Revenue Analysis, Key Players, Regional Analysis by Forecast to 2026

The report provides rational insights along with historical and forecast data to aid in better understanding of the Global Valvular Heart Disease Treatment Market. The report provides a comprehensive analysis...

ABT : 89.36 (+0.54%)
BSX : 43.02 (+2.04%)
CRY : 26.24 (-3.35%)
EW : 235.31 (+2.51%)
LIVN : 70.00 (-0.67%)
MDT : 113.77 (+0.99%)
NVCN.TO : 3.76 (+7.12%)
Transcatheter Devices Market To Significantly Increase Revenues in 2019 to 2027

BSX : 43.02 (+2.04%)
CRY : 26.24 (-3.35%)
EW : 235.31 (+2.51%)
NVCN.TO : 3.76 (+7.12%)
% Return Seen to Date on SmarTrend Cryolife Inc Call (CRY)

SmarTrend identified a Downtrend for Cryolife Inc (NYSE:CRY) on December 11th, 2019 at $25.62. In approximately 2 months, Cryolife Inc has returned 17.14% as of today's recent price of $30.01.

CRY : 26.24 (-3.35%)
CryoLife Announces Release Date and Teleconference Call Details for 2019 Fourth Quarter and Year-end Financial Results

CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2019 fourth quarter and year-end financial results will be released on Thursday,...

CRY : 26.24 (-3.35%)
17.5% Return Seen to Date on SmarTrend Cryolife Inc Call (CRY)

SmarTrend identified an Uptrend for Cryolife Inc (NYSE:CRY) on December 11th, 2019 at $25.62. In approximately 1 month, Cryolife Inc has returned 17.49% as of today's recent price of $30.10.

CRY : 26.24 (-3.35%)
Zacks.com featured highlights include: Carrols, Braskem, FirstService and CryoLife

Zacks.com featured highlights include: Carrols, Braskem, FirstService and CryoLife

ETSY : 53.18 (-0.26%)
CRY : 26.24 (-3.35%)
BAK : 14.70 (+2.58%)
FSV : 109.71 (-0.77%)
TAST : 5.20 (+4.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade CRY with:

Business Summary

CryoLife, Inc. is a leader in medical device manufacturing and distribution and in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries. It operates throughout the U.S. and internationally. CryoLife manufactures and distributes BioGlue Surgical...

See More

Key Turning Points

2nd Resistance Point 27.77
1st Resistance Point 27.01
Last Price 26.24
1st Support Level 25.85
2nd Support Level 25.45

See More

52-Week High 33.00
Fibonacci 61.8% 28.32
Fibonacci 50% 26.88
Last Price 26.24
Fibonacci 38.2% 25.44
52-Week Low 20.76

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar